ETCTN Trials by Disease/ Treatment Area: Breast Cancer

**Triple negative breast cancer (TNBC)**

- Early stage TNBC
- Locally advanced/ metastatic TNBC

**Hormone receptor positive (HR+)**

- Locally advanced/ metastatic ER+ and/or PR+/HER2
- Locally advanced/ metastatic ER+/HER2-

**TNBC or HR+**

- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)

**HER2 positive**

- With residual cancer burden (TNBC or ER+ and/or PR- HER2-BC)
- Expansion: Locally advanced/ metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**Breast Cancer**

- 10013: Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)
- ▼ 9876: Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer
- 10146: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
- 9881: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, SCLC)
- ▼ 10031: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple Negative Breast Cancer (Dose escalation: solid tumors)
- 10287: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)
- 10195: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
- ▼ 10131: A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Dose escalation: Solid tumors with PTEN or PIK3CB Mutations; Expansion cohorts include: breast, prostate, and other solid tumors.)
- 10291: A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
- ▼ 9844: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors
- 10296: Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation, PTEN Mutation or PTEN Loss

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: September 17, 2019